繁体中文
设为首页
加入收藏
当前位置:药品说明书与价格首页 >> 心血管系统 >> 新药推荐 >> 西药 >> Namenda XR(盐酸美金刚缓释胶囊)

Namenda XR(盐酸美金刚缓释胶囊)

2013-08-11 17:07:35  作者:新特药房  来源:互联网  浏览次数:425  文字大小:【】【】【
简介:2010年6月,美国FDA批准了Forest和Merz两制药公司联合开发的盐酸美金刚(memantine hydrochloride)28mg缓释胶囊NamendaXR,用于一日1次口服治疗中至重度阿尔茨海默病患者.NAMENDA XR CAP TITRATION PACK 里面含 ...

2010年6月,美国FDA批准了Forest和Merz两制药公司联合开发的盐酸美金刚(memantine hydrochloride)28mg缓释胶囊NamendaXR,用于一日1次口服治疗中至重度阿尔茨海默病患者.
NAMENDA XR CAP TITRATION PACK
里面含 Contains 28 capsules (7粒 x 7 mg, 7粒 x 14 mg, 粒7 x 21 mg, 7粒 x 28 mg)
NAMENDA XR CAP 7MG 30
NAMENDA XR CAP 14MG 30
NAMENDA XR CAP 21MG 30

NAMENDA XR™ (memantine hydrochloride) extended-release capsules are indicated for the treatment of moderate to severe dementia of the Alzheimer's type.
Important Safety Information
Contraindications
•NAMENDA XR is contraindicated in patients with known hypersensitivity to memantine hydrochloride or to any excipients used in the formulation.
Warnings and Precautions
•NAMENDA XR should be used with caution under conditions that raise urine pH (including alterations by diet, drugs and the clinical state of the patient). Alkaline urine conditions may decrease the urinary elimination of memantine, resulting in increased plasma levels and a possible increase in adverse effects.
•NAMENDA XR has not been systematically evaluated in patients with a seizure disorder.
Adverse Reactions
•The most commonly observed adverse reactions seen in patients administered NAMENDA XR (28 mg/day) in a controlled clinical trial, defined as those occurring at a frequency of at least 5% in the NAMENDA XR group and at a higher frequency than placebo were headache (6% vs 5%), diarrhea (5% vs 4%), and dizziness (5% vs 1%).
Drug Interactions
•No drug-drug interaction studies have been conducted with NAMENDA XR, specifically. The combined use of NAMENDA XR with other NMDA antagonists (amantadine, ketamine, or dextromethorphan) has not been systematically evaluated and such use should be approached with caution.
Dosage and Administration
•The recommended starting dose of NAMENDA XR is 7 mg once daily. The recommended target dose is 28 mg once daily. The dose should be increased in 7 mg increments to 28 mg once daily. The minimum recommended interval between dose increases is one week, and only if the previous dose has been well tolerated. The maximum recommended dose is 28 mg once daily.
•It is recommended that a patient who is on a regimen of 10 mg twice daily of NAMENDA tablets be switched to NAMENDA XR 28 mg once-daily capsules the day following the last dose of a 10 mg NAMENDA tablet. There is no study addressing the comparative efficacy of these 2 regimens.
•It is recommended that a patient with severe renal impairment who is on a regimen of 5 mg twice daily of NAMENDA tablets be switched to NAMENDA XR 14 mg once-daily capsules the day following the last dose of a 5 mg NAMENDA tablet.
Special Populations
•NAMENDA XR should be administered with caution to patients with severe hepatic impairment.
•A target dose of 14 mg/day is recommended in patients with severe renal impairment (creatinine clearance of 5-29 mL/min, based on the Cockcroft-Gault equation).

责任编辑:admin


相关文章
Namenda XR(memantine hydrochloride)盐酸美金刚缓释胶囊
Solanezumab
阿尔茨海默病临床药物治疗
盐酸美金刚片(易倍申)治疗阿尔茨海默病的基础研究
易倍申-(美金刚片)在国内外临床使用的疗效获广泛认可
易倍申与安理申二种药物治疗老人痴呆症临床疗效比较
Tacrine (盐酸他克林胶囊)
思博海多奈哌齐治疗阿尔茨海默病
博司捷GM1对阿尔茨海默病的影响
神经节苷脂GM1对阿尔茨海默病的作用机制
 

最新文章

更多

· 依度沙班片|Lixiana(ed...
· DuoPlavin(阿司匹林/氯...
· Argatroban Injection(...
· Plavix(Clopidogrel Bi...
· 替卡格雷片BRILIQUE(tic...
· DOBUPUM Injection syri...
· Prestalia(Perindopril ...
· Repatha(evolocumab)溶液...
· PRALUENT(alirocumab in...
· ENTRESTO tablets(奥帕...

推荐文章

更多

· 依度沙班片|Lixiana(ed...
· DuoPlavin(阿司匹林/氯...
· Argatroban Injection(...
· Plavix(Clopidogrel Bi...
· 替卡格雷片BRILIQUE(tic...
· DOBUPUM Injection syri...
· Prestalia(Perindopril ...
· Repatha(evolocumab)溶液...
· PRALUENT(alirocumab in...
· ENTRESTO tablets(奥帕...

热点文章

更多

· Plavix(Clopidogrel Bi...
· Argatroban Injection(...
· DuoPlavin(阿司匹林/氯...
· 依度沙班片|Lixiana(ed...